Stator labels the same single cell multiply, not just by type and subtype, but also by state such as activation, maturity or cell cycle sub-phase, through deriving higher-order gene expression ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab ...

In a phase 3, randomized trial, we enrolled patients with local or regional cutaneous squamous-cell carcinoma, after surgical resection and postoperative radiotherapy, at high risk for recurrence ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer (SCLC). The DLL3xCD3 bispecific has shown that it can help patients live ...

Candid's T-cell engager shopping spree rolls on with WuXi Biologics pact worth up to $925M As for Juri, very little is publicly known about the TCG Labs Soleil-created company.

The process of necrosis, a form of cell death, may represent one of the most promising ways to change the course of human aging, disease and even space travel, according to a new study. The ...

While immunotherapy has revolutionized treatment of many solid tumors, immune checkpoint inhibitors have generally failed to demonstrate clinical utility in prostate cancer (PC). 1,2 T-cell engager ...